RADNOR, Pa.--(BUSINESS WIRE)--Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL – stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints. The top-line data are being presented for the first time today at the First World Congress of Cutaneous Lymphomas in Chicago, IL, by Stuart R. Lessin, MD, lead investigator of the study and director of dermatology at Fox Chase Cancer Center. Yaupon intends to file a New Drug Application (NDA) with the FDA later this year.
